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Abstract
Background: Obesity has been proposed as a potential protective factor against lung cancer. We examined the
association between BMI and lung cancer risk in a pooled analysis based on nested case-control studies from four
cohort studies.
Methods: A case-control study was nested within four cohorts in USA, Europe, China and Singapore that included
4172 cases and 8471 control subjects. BMI at baseline was calculated as weight in kilograms divided by height in
meters squared (kg/m2), and classified into 4 categories: underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25),
overweight (25 ≤ BMI < 30) and obese (≥30). Odds ratios (ORs) and 95% confidence intervals (CIs) for BMI-lung
cancer associations were estimated using unconditional logistic regression, adjusting for potential confounders.
Results: Considering all participants, and using normal weight as the reference group, a decreased risk of lung
cancer was observed for those who were overweight (OR 0.77, 95% CI: 0.68–0.86) and obese (OR 0.69, 95% CI: 0.59–
0.82). In the stratified analysis by smoking status, the decreased risk for lung cancer was observed among current,
former and never smokers (P for interaction 0.002). The adjusted ORs for overweight and obese groups were 0.79
(95% CI: 0.68–0.92) and 0.75 (95% CI: 0.60–0.93) for current smokers, 0.70 (95% CI: 0.53–0.93) and 0.55 (95% CI: 0.37–
0.80) for former smokers, 0.77 (95% CI: 0.59–0.99), and 0.71 (95% CI: 0.44–1.14) for never smokers, respectively. While
no statistically significant association was observed for underweight subjects who were current smokers (OR 1.24,
95% CI: 0.98–1.58), former smokers (OR 0.27, 95% CI: 0.12–0.61) and never smokers (OR 0.83, 95% CI: 0.5.-1.28).
Conclusion: The results of this study provide additional evidence that obesity is associated with a decreased risk of
lung cancer. Further biological studies are needed to address this association.
Keywords: Body mass index, Obesity, Overweight, Lung cancer
Background
Lung cancer is the most common cancer and the leading
cause of cancer-related deaths worldwide, with an esti-
mated 1.82 million lung cancer cases and 1.59 million
deaths in 2012 [1]. Incidence and mortality rates for lung
cancer are higher among men than women, with 1.2 mil-
lion cases and 1 million deaths estimated in men and
580,000 cases and 490,000 deaths estimated in women
in 2012 [2]. The incidence of lung cancer varies by age,
sex, geographical location and histological type [3, 4].
These variations are mostly determined by differences in
smoking patterns and exposures to other lung carcino-
gens [5–8]. Smoking, second-hand smoke, air pollution,
asbestos, radon, and occupational exposure to chemical
carcinogens are well-known risk factors for lung cancer
[9–13]. Furthermore, a comprehensive review of epi-
demiological evidence revealed that low consumption of
fruits and vegetables contribute to an increased risk of
lung cancer [14, 15].
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Obesity is linked to an increased risk of many cancers,
including cancers of the breast (in post-menopausal
women), endometrium, esophagus, gallbladder, kidney,
colorectal, and pancreas [16]. By contrast, body mass
index (BMI, a proxy measure of obesity) of ≥30 kg/m2,
has been inversely associated with the risk of lung can-
cer in several case-control and cohort studies [17–27].
Besides, some of these studies have also shown that low
BMI is associated with an increased risk of lung cancer
[19, 20, 25, 28, 29]. Two recent meta-analyses have pro-
vided more evidence supporting that excess weight could
significantly decrease the risk of lung cancer [30, 31].
There are some methodological issues in examining the
association between BMI and lung cancer risk. Firstly,
smoking is an established risk factor for lung cancer and
is also associated with body weight, which may confound
the relation between BMI and lung cancer [32, 33].
Smokers tend to be leaner than non-smokers; heavy
smokers tend to have greater body weight than light
smokers, which likely reflects an unhealthy lifestyle (for
instance, poor diet and low level of physical activity)
[32]. In fact, studies that restricted the analysis to never
smokers, the association between BMI and lung cancer
disappeared [34, 35]. Secondly, preclinical effects of lung
cancer and associated weight loss may distort the associ-
ation between BMI and lung cancer, which is often re-
ferred to as reverse causation [20, 36]. Studies that had a
short follow-up or studies in which weight was reported
shortly before cancer diagnosis are more prone to re-
verse causality. To our knowledge, few studies have
attempted to tackle these methodological issues using
Mendelian randomization approach [37–39]. However,
this method has not been extended to evaluate non-
linear associations. Apart from these, some epidemio-
logical studies have failed to find the inverse association
between BMI and lung cancer risk [40, 41]. In addition,
histological types of lung cancer may exemplify largely
divergent diseases with different etiologies, but studies
examining the association between BMI and lung cancer
by histological type are limited [24, 42, 43].
Hence, the aim of the present study was to examine
the association between BMI and lung cancer risk in a
pooled analysis based on nested case-control studies
from four cohort studies in USA, Europe, China and
Singapore. The large sample size of this nested study
allowed us to assess the association by gender, smoking
status and histological types of lung cancer.
Methods
Study population
This project was conducted under the framework of the
International Lung Cancer Consortium (ILCCO). ILCCO
was established in 2004 with the objective to pool equiva-
lent data and maximize resource sharing and statistical
power of epidemiological studies of lung cancer [44]. Four
ILCCO studies are included in this pooled analysis. The
collaborating cohorts have been described in detail previ-
ously [45–51]. These are the Carotene and Retinol Efficacy
Trial (CARET), European Prospective Investigation into
Cancer and Nutrition Study (EPIC), Shanghai Cohort
Study (SCS), and Singapore Chinese Health Study (SCHS).
A summary of selected characteristics of these cohorts is
presented in Table 1.
Cases ascertainment and data collection method
Cases included were all incident primary lung cancer
(International Classification of Diseases-Oncology (ICD-
O) 3rd edition and included all invasive cancers coded to
C33–34). All histological types were included. Case ascer-
tainment varied among studies but included linking
Table 1 Characteristics of participating cohorts
Study Location Enrollment
years
Baseline
cohort
Age at
enrollment
Follow-up
mean years
Source of
height and
weight data
Cases/Controls
(N = 4172/8471)
Matching
Carotene and Retinol
Efficacy Trial
USA 1985–1994 18,314 45–69 11.5 Measured 787/1564 Age (± 4 years), sex, race,
enrollment year (2-years
intervals), baseline measures
of smoking status (current
or former), asbestos exposure
(yes or no) and duration
of follow up
European Prospective
Investigation into
Cancer and Nutrition
Europe 1992–2000 521,468 35–70 10.1 Mostly Measured,
except for some
EPIC centers a
1242/2622 Age, sex, smoking status,
and country of recruitment
Shanghai Cohort
Study
China 1986–1989 18,244 45–64 15.8 Self-reported 965/1929 Age and sex
Singapore Chinese
Health Study
Singapore 1993–1998 63,257 45–74 10.0 Self-reported 1178/2356 Age and sex
aOxford cohort, Norwegian cohort and approximately two-thirds of the French cohort, height and weight were self-reported
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participants to cancer registries, health insurance records,
medical records, self-report, and next of kin reports. Most
of the cases among studies were histologically confirmed.
In each study, two lung cancer-free controls were
matched per case (controls were cancer-free at the time
of diagnosis of the matched case). Mostly, controls were
matched to cases on age (plus/minus 5 years) and sex.
Some cohorts used more stringent matching on other
variables (Table 1). In each study, two lung cancer-free
controls were matched per case.
Data on demographics and possible confounders were
collected among studies through a self-administered
written questionnaire (EPIC and CARET) or in- person
interviews (EPIC, SCS and SCHS). At recruitment, mea-
surements of height and weight were taken for all the
participants of the CARET study and for most of the
EPIC cohort (Table 1). In the SCS and SCHS cohort and
for some of the EPIC participants (mainly for Oxford co-
hort, Norwegian cohort and approximately two-thirds of
the French cohort) height and weight at baseline were
self-reported. A detailed description of data collection
methods has been published previously by the individual
studies [45–51]. From each study, baseline information
on anthropometric measurements (height and weight),
history of cigarette smoking, sex, age at enrollment and
diagnosis, year of last observation/follow-up, and level of
education was requested.
Statistical analysis
Unconditional logistic regression models were used to es-
timate odds ratios (ORs) and 95% confidence intervals
(CIs) for the association between BMI and lung cancer
risk. BMI at baseline was calculated as weight in kilograms
divided by the square of the height in meters (kg/m2) and
classified into 4 categories according to the WHO inter-
national classification: underweight (BMI < 18.5), normal
weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and
obese (≥30). Normal weight was used as the reference cat-
egory. Pack-years of smoking were computed by using the
formula: (number of years smoked x mean number of cig-
arettes smoked per day)/20. In cases, time elapsed was
computed as the difference between the age at enrolment
and diagnosis, whereas in controls, it was calculated as the
difference between age at enrolment and last follow-up/
observation.
All models were adjusted for sex, study center, age (< 45,
45–49, 50–54, 55–59, 60–64, 65–69, ≥70), time elapsed
(< 2, 2–8, 9–14, 15–20, ≥20), pack-years of smoking (0, <
20, 20–29, 30–39, 40–49, and ≥50), and education level
(none, primary school, middle/vocational, secondary
school, postsecondary/technical and university). Subgroup
analyses were performed for gender, smoking status and
histologic types of lung cancer. Deviation of multiplicative
interactions of BMI with sex and smoking status was
explored by including an interaction term along with the
main effect term in the adjusted model. The statistical
significance of the interaction term was evaluated using
likelihood ratio tests. To investigate possible reverse caus-
ation, sensitivity analysis was performed by excluding lung
cancer cases diagnosed in the first 3 years of follow up.
Additional, sensitivity analysis was also conducted by
eliminating two studies (SCS and SCHS), where height
and weight were self-reported. We tested for heterogen-
eity across studies using the Q and I2 statistic [52]. To
graphically display odds ratios representing the dose-
response association for BMI and lung cancer risk, we
used the restrictive cubic spline (RCS) function with 4
knots (5, 10, 20, and 40 percentile) in a multivariate un-
conditional logistic regression model as described above.
The selection of model (4 knots) was based on the lower
Akaike Information Criteria (AIC). This analysis was
performed using the RCS_Reg SAS Macro created by
Desquilbet and Mariotti [53]. All analyses were performed
using the SAS 9.3 software (SAS Institute, Cary, NC) and
a p-value < 0.05 was considered as statistically significant.
Results
The study included 4172 lung cancer cases and 8471
controls aged 35 to 74 years (Table 1). Baseline charac-
teristics of participants are presented in Table 2. Of the
4172 lung cancer cases, 3043 were men and 1129 were
women. Compared with controls, cases were slightly
older, had a lower education level and higher prevalence
of current smoking. The average age at lung cancer on-
set in cases was 68.0 years, and the average time elapsed
from enrollment to diagnosis of lung cancer in cases was
8.3 years.
In the total participants, cases had slightly lower mean
weight compared with controls (68.2 and 69.7 kg). Mean
height was similar (1.67 m). Fifty-two percent of cases
and 51% of controls had BMI in the normal range, 27%
of cases and 32% of controls were overweight, and 9% of
cases and 11% of controls were obese.
Table 3 displays adjusted ORs and 95% CIs for lung
cancer according to baseline BMI categories. Consider-
ing all participants, and using normal weight as the
reference group, a decreased risk of lung cancer was
observed for those who were overweight (OR 0.77, 95%
CI: 0.68–0.86) and obese (OR 0.69, 95% CI: 0.59–0.82)
whereas no statistically significant association was ob-
served for underweight subjects (OR 1.03, 95% CI: 0.84–
1.25). When stratified by gender, the inverse association
observed between BMI and lung cancer risk was similar
for overweight and obese men (OR 0.71, 95% CI: 0.62–
0.81 for overweight group; and OR 0.63, 95% CI: 0.52–
0.78 for obese group); the association for women was
slightly attenuated (OR 0.80, 95% CI: 0.63–1.02 for
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overweight group; and OR 0.70, 95% CI: 0.51–0.97 for
obese group) (Table 3).
To further investigate the association between BMI
and lung cancer risk among subgroups, we stratified the
analyses by smoking status (Table 4). In both genders
combined, the decreased risk for lung cancer was ob-
served among current, former, and never smokers (P for
interaction 0.002). The adjusted ORs for overweight and
obese groups were 0.79 (95% CI: 0.68–0.92) and 0.75 (95%
CI: 0.60–0.93) for current smokers, 0.70 (95% CI: 0.53–
0.93) and 0.55 (95% CI: 0.37–0.80) for former smokers,
0.77 (95% CI: 0.59–0.99), and 0.71 (95% CI: 0.44–1.14) for
never smokers, respectively. When separate analysis was
performed by gender, the decreased risk for lung cancer
was observed among both former and current male and
female smokers but it did not reach statistical significance
among female smokers, which could be explained by few
number of female cases (Table 4).
We performed RCS regression to describe the nonlin-
ear dose-response association between BMI and risk of
lung cancer (Fig. 1). In all the participants, we found a
significant nonlinear dose-response association between
BMI and risk of lung cancer (P nonlinearity 0.001; Fig. 1a).
After stratifying by gender, the evidence of a nonlinear
association was observed in men (P nonlinearity 0.009; Fig.
1b) but not in women (P nonlinearity 0.11; Fig. 1c). After
stratifying by smoking status, the nonlinear association
was observed in former and current smokers (P nonlinear-
ity 0.006; Fig. 1d,e respectively) but not in never smokers
(P nonlinearity 0.14; Fig. 1f ).
We also examined the association between BMI and
risk of histological types of lung cancer (Table 5). When
we stratified the analysis by histological types, the reduc-
tion in risk was observed for all histological types but it
was statistically significant for adenocarcinoma and large
Table 2 Selected characteristics of participants
Characteristic Cases
(n = 4172)
N (%)
Controls
(n = 8471)
N (%)
P value (X2)
Sex 0.37
Men 3043 (72.9) 6135 (72.4)
Women 1129 (27.1) 2336 (27.6)
Age <.0001
< 45 76 (1.8) 197 (2.3)
45–49 211 (5.1) 980 (11.6)
50–54 602 (14.4) 1720 (20.3)
55–59 1010 (24.2) 2165 (25.5)
60–64 1216 (29.2) 2024 (23.9)
65–69 731 (17.5) 1070 (12.6)
≥ 70 326 (7.8) 324 (3.8)
BMI (kg/m2) a <.0001
Underweight 250 (5.9) 408 (4.8)
Normal weight 2150 (51.5) 4276 (50.5)
Overweight 112 (26.7) 2746 (32.4)
Obese 373 (8.9) 934 (11.0)
Missing 287 (6.9) 107 (1.3)
Education <.0001
None 529 (12.7) 699 (8.3)
Primary 1515 (36.3) 2518 (29.7)
Middle/Vocational 851 (20.4) 2109 (24.9)
Secondary 457 (11.0) 1060 (12.5)
Postsecondary/Technical 312 (7.5) 665 (7.9)
University 381 (9.1) 1164 (13.7)
Unknown/not specified 26 (0.6) 51 (0.6)
Missing 101 (2.4) 205 (2.4)
Smoking status <.0001
Never 571 (13.7) 3144 (37.1)
Former 694 (16.6) 1735 (20.5)
Current 2892 (69.3) 3556 (42.0)
Missing b 15 (0.36) 36 (0.4)
Pack-years of smoking <.0001
0 571 (13.7) 3144 (37.1)
< 20 547 (13.1) 1562 (18.4)
20–29 554 (13.3) 850 (10.0)
30–39 691 (16.6) 891 (10.5)
40–49 817 (19.6) 829 (9.8)
≥ 50 831 (19.9) 892 (10.5)
Missing 161 (3.9) 303 (3.6)
Age at diagnosis of lung cancer, y
Mean (SD) 68.0 (8.1) –
Median (range) 68.2 (38.1–91.0)
Table 2 Selected characteristics of participants (Continued)
Characteristic Cases
(n = 4172)
N (%)
Controls
(n = 8471)
N (%)
P value (X2)
Time elapsed, y
Mean (SD) 8.3 (5.4) c 13.3 (5.1) d
Median (range) 7.3 (0–27) 13.0 (0–28)
Histological Type
Adenocarcinoma 1182 (42.6)
Squamous cell carcinoma 897 (32.6)
Large cell carcinoma 221 (7.9)
Small cell carcinoma 473 (17.1)
aUnderweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤
BMI < 30) and obese (BMI ≥ 30)
bSubjects who had missing cigarettes smoked per day and duration
of smoking
cPeriod between enrollment and diagnosis
dPeriod between enrollment and last follow-up/observation
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cell carcinoma. The adjusted ORs for overweight and
obese groups were 0.74 (95% CI: 0.62–0.87) and 0.65
(95% CI: 0.50–0.85) for adenocarcinoma, 0.69 (95% CI:
0.48–0.99) and 0.49 (95% CI: 0.26–0.92) for large cell
carcinoma, respectively.
The risk estimates did not change substantially in
the sensitivity analysis after exclusion of lung cancer
cases diagnosed in the first 3 years of follow-up
(Additional file 1: Table S1). In addition, analyses
using measured BMI, which included two studies (CARET
and EPIC) yielded similar results (data not shown).There
was mild heterogeneity between cohorts for the BMI-lung
cancer results (P value = 0.12, I2 = 50%) (Additional file 2:
Figure S1).
Discussion
In this pooled analysis of cohorts involving 12,643 sub-
jects (4172 lung cancer cases and 8471 controls), we
found a statistically significant inverse, dose-dependent
association between BMI and lung cancer risk. This in-
verse association was present in current, former and
never smokers and the effect was more evident for the
subjects with a BMI of > 30 (kg/m2).
Table 3 Adjusted odds ratio of lung cancer according to BMI categories
Men and Women Men Women
Cases Controls Adjusted Cases Controls Adjusted Cases Controls Adjusted
BMI (kg/m2) a (N = 4172) (N = 8471) OR (95% CI) b (N = 3043) (N = 6135) OR (95% CI) c (N = 1129) (N = 2336) OR (95% CI) c
Underweight 250 408 1.03 (0.84–1.25) 196 310 1.06 (0.85–1.32) 54 98 0.85 (0.52–1.39)
Normal weight 2150 4276 Reference 1607 3155 Reference 543 1121 Reference
Overweight 1112 2746 0.77 (0.68–0.86) 810 2004 0.71 (0.62–0.81) 302 742 0.80 (0.63–1.02)
Obese 373 934 0.69 (0.59–0.82) 256 628 0.63 (0.52–0.78) 117 306 0.70 (0.51–0.97)
Missing 287 107 – 174 38 – 113 69 –
aUnderweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥ 30)
bAdjusted for age, gender, study center, time elapsed, pack-years of smoking and education level
cAdjusted for age, study center, time elapsed, pack-years of smoking and education level
Table 4 Adjusted odds ratio of lung cancer by smoking status according to BMI categories
BMI (kg/m2) a Men and Women Men Women
Cases Controls Adjusted OR (95% CI) b Cases Controls Adjusted OR (95% CI) c Cases Controls Adjusted OR (95% CI) c
Never Smokers
Underweight 33 161 0.83 (0.53–1.28) 15 97 0.88 (0.49–1.60) 18 64 0.84 (0.42–1.68)
Normal weight 334 1794 Reference 169 1159 Reference 165 635 Reference
Overweight 117 916 0.77 (0.59–0.99) 46 540 0.74 (0.51–1.06) 71 376 0.75 (0.51–1.11)
Obese 29 233 0.71 (0.44–1.14) 5 110 0.55 (0.22–1.40) 24 123 0.73 (0.40–1.36)
Missing 58 40 – 19 15 – 39 25 –
Former Smokers
Underweight 10 58 0.27 (0.12–0.61) 8 51 0.26 (0.11–0.61) 2 7 0.27 (0.02–3.69)
Normal weight 262 609 Reference 203 477 Reference 59 132 Reference
Overweight 272 729 0.70 (0.53–0.93) 224 599 0.66 (0.48–0.91) 55 130 0.77 (0.36–1.65)
Obese 105 297 0.55 (0.37–0.80) 83 230 0.51 (0.33–0.79) 22 67 0.67 (0.27–1.67)
Missing 38 42 26 15 – – 27 –
Current Smokers
Underweight 207 189 1.24 (0.98–1.58) 173 162 1.26 (0.98–1.63) 34 27 0.82 (0.38–1.76)
Normal weight 1549 1860 Reference 1234 1511 Reference 315 349 Reference
Overweight 710 1085 0.79 (0.68–0.92) 537 853 0.75 (0.63–0.88) 173 232 0.87 (0.62–1.23)
Obese 237 400 0.75 (0.60–0.93) 167 286 0.72 (0.55–0.92) 70 114 0.73 (0.46–1.15)
Missing 189 22 – 127 6 – 62 16 –
aUnderweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥ 30)
bAdjusted for age, gender, study center, time elapsed, pack-years of smoking (except for never smokers) and education level
cAdjusted for age, study center, time elapsed, pack-years of smoking (except for never smokers) and education level
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Our study found that being overweight or obese is as-
sociated with a decreased risk of lung cancer. This is
consistent with a recent meta-analysis including 31 stud-
ies (20 cohorts, 11 case-control). The pooled relative
risks in this study were 0.74 (95% CI: 0.68–0.80) for
overweight (BMI 25–29.9 kg/m2) and 0.71 (95% CI:
0.68–0.80) for obese (BMI ≥30 kg/m2), compared with
normal weight (BMI 18.5–24.9 kg/m2) [30]. More re-
cently Duan et al. conducted a dose-response meta-
analysis, which included 29 cohort studies and found
evidence of a non-linear association between BMI and
lung cancer risk (P nonlinearity < 0.001) [31]. Compared
with individuals with a BMI of 18.5–24.9 kg/m2, the
summary relative risks for those with a BMI of 30 kg/m2
and BMI 35 kg/m2 were 0.91 (95% CI: 0.85–0.98) and
0.81 (95% CI: 0.72–0.91), respectively [31]. A cohort
study conducted in the UK, which was not included in
this meta-analysis, also showed an inverse association
between higher BMI and lung cancer risk [54].
In gender-stratified analysis, we observed similar re-
sults in both men and women. The findings of previous
meta-analyses also indicated no gender differences in the
association between BMI and lung cancer risk [30, 31].
Given that smoking is the most important risk factor
for lung cancer and associated with body weight, we
stratified our analyses by smoking status and found a
significant inverse association between BMI and lung
cancer risk among current, former and never smokers.
This is in line with results of previous meta-analysis
[31]. In this meta-analysis, the pooled RRs for over-
weight and obese groups were 0.91 (95% CI: 0.85–0.98)
and 0.77 (95% CI: 0.69–0.85) for ex-smokers, 0.79 (95%
CI: 0.71–0.87), 0.72 (95% CI: 0.66–0.78) for current
smokers and 0.86 (95% CI: 0.78–0.94) and 0.86 (95% CI:
0.75–0.98) for non-smokers respectively [31].
In our study, stratification by histological subtype
showed that overweight and obese was significantly in-
versely associated with risk of adenocarcinoma and large
cell carcinoma. The results of stratified analysis in the
previous meta-analysis reported a lower risk for adeno-
carcinoma and squamous cell carcinoma [30, 31].
Our study found no association between being under-
weight and risk of lung cancer. However, stratification
by smoking status showed a non-significant increased
risk for lung cancer in current smokers who were under-
weight (OR 1.24, 95% CI: 0.98–1.58). Results of a recent
meta-analysis reported a significant positive association
between low BMI and lung cancer risk (pooled RR 1.24;
95% Cl: 1.20–1.27; for underweight vs. normal weight)
[31]. But, this association was confined to current
smokers (RR 1.31, 95% CI: 1.10–1.57) and no statistically
significant association was found in ex-smokers and
never smokers (RR 1.40, 95% CI: 0.82–2.36 and RR 1.18,
95% CI: 0.90–1.54, respectively) [31].
Fig. 1 Adjusted dose-response association between BMI and risk of lung cancer: (a) All participants (b) Men (c) Women (d) Former smokers
(e) Current smokers (f) Never smokers. BMI was coded using an RCS function with four knots arbitrarily located at the 5th, 10th, 20th and 40th
percentiles. The y-axis represents the adjusted odds ratio for lung cancer risk for any value of BMI compared to individuals with a BMI of 22.0
kg/m2 (median value of BMI). Dashed lines are 95% CI. Knots are represented by dots
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A few biological mechanisms support the plausibility
for the inverse association between BMI and lung cancer
risk. Environmental Geno toxicants like polycyclic aro-
matic hydrocarbons (PAHs) that derived from smoking
and occupational exposure, are known to cause DNA
damage that results in a dose-dependent risk of lung
cancer [55]. Among PAHs, benzo-α-pyrene is the most
widely studied element, and its ability to induce lung tu-
mors upon inhalation is well recognized [56]. Interest-
ingly, studies have found inverse associations between
BMI and benzo-α-pyrene DNA adduct levels among
smokers, suggesting that increased body fat impacts ad-
duct levels, possibly by affecting the distribution of the
carcinogen [57, 58]. In addition, inverse associations
have been reported between BMI and levels of urinary
8-hydroxydeoxyguanosine (8-OHdG), a marker of oxida-
tive DNA damage in smokers [59, 60]. Brennan et al. re-
ported that FTO genotype, a genetic marker of obesity
which is related to increased BMI, was associated with a
decreased risk of lung cancer [37]. On the other hand,
two recent Mendelian randomization (MR) analyses for
BMI and lung cancer, showed increased BMI was posi-
tively associated with lung cancer risk [38, 39]. However,
the MR assumptions can be confounded by the potential
pleiotropic effects of genetic variants associated with
both BMI and smoking behavior [38, 39]. Recently Dik
et al. conducted a large-scale genome-wide analysis of
the association between BMI and DNA methylation and
found increased BMI is associated with increased methyla-
tion at the HIF3A locus in blood and in adipose tissue [61].
HIF3A is an element of the hypoxia-inducible transcription
factor (HIF) that controls a wide variety of cellular and
physiological responses to reduced oxygen concentrations
by controlling the expression of several target genes [62].
Studies have observed that HIF3A can regulate many genes
associated with angiogenesis, in addition to cell survival
and apoptosis [63, 64]. These observations suggest that
HIF3A may play a role in lung carcinogenesis [60]. How-
ever, further molecular-epidemiological studies are needed
in exploring the underlying carcinogenic mechanisms asso-
ciating BMI with lung cancer risk.
The major strengths of this study include its prospective
cohort-based nested case-control design, large sample size,
and available information on potential confounders. As
the study population was largely a nested sample from dif-
ferent prospective cohort studies and BMI was measured
before lung cancer diagnosis, hence the possibility of se-
lection and recall bias is minimal. In addition, we were
able to perform the analyses by gender, smoking status
and histological types. Our study also has some limita-
tions. First, the use of some self-reported exposure infor-
mation. However, separate analyses using measured BMI
yielded similar results. In addition, previous studies have
noted that even though self-reported height tends to be
overestimated and weight tends to be underestimated, the
self-reported values are highly correlated with the mea-
sured values [65–67]. Second, our analyses were based on
self-reported cigarette smoking at baseline, and informa-
tion on change in smoking habits during follow-up was
not available from studies; if smoking habits varied over
time, this could have had some effect on the results. How-
ever, we observed similar patterns for former and current
smokers; hence it is unlikely to alter the results if current
smokers became former smokers during follow-up. Third,
adjustment for pack-years of smoking may not adequately
control for confounding effect of cigarette smoking, thus
residual confounding by smoking may still exist. Last,
there was a wide range of time elapsed between BMI
measurement (collected at baseline) and the date of diag-
nosis. However, sensitivity analysis examining this time
elapsed by excluding the first 3 years of follow-up did not
change risk estimates substantially. Hence, it argues
Table 5 Adjusted odds ratio of lung cancer by histological type
according to BMI categories
BMI (kg/m2) a Cases Controls Adjusted OR (95%CI) b
Adenocarcinoma
Underweight 84 408 1.17 (0.89–1.54)
Normal weight 623 4288 Reference
Overweight 290 2752 0.74 (0.62–0.87)
Obese 90 936 0.65 (0.50–0.85)
Missing 95 106 –
Squamous cell carcinoma
Underweight 56 408 1.06 (0.76–1.47)
Normal weight 445 4288 Reference
Overweight 259 2752 0.89 (0.74–1.08)
Obese 85 936 0.77 (0.57–1.03)
Missing 52 106 –
Large cell carcinoma
Underweight 15 408 0.98 (0.55–1.76)
Normal weight 117 4288 Reference
Overweight 54 2752 0.69 (0.48–0.99)
Obese 13 936 0.49 (0.26–0.92)
Missing 22 106 –
Small cell carcinoma
Underweight 14 408 0.62 (0.35–1.11)
Normal weight 208 4288 Reference
Overweight 155 2752 0.90 (0.70–1.15)
Obese 57 936 0.79 (0.56–1.12)
Missing 39 106 –
aUnderweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤
BMI < 30) and obese (BMI ≥ 30)
bAdjusted for age, gender, study center, time elapsed, pack-years of smoking
and education level
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against an effect of preclinical disease-related changes in
anthropometric measures (reverse causation).
Conclusions
In conclusion, the results of this study provide additional
evidence that obesity is associated with a decreased risk
of lung cancer. Further biological studies are needed to
address this association.
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